<DOC>
	<DOCNO>NCT02698501</DOCNO>
	<brief_summary>The purpose study determine whether anti-TSLP decrease airway hyperresponsiveness patient asthma already daily treatment inhaled corticosteroid . The investigator expect airway hyperresponsiveness decrease treatment anti-TSLP , happens due change type mast cell lung . Also , investigator expect decrease inflammatory cell mediator measure material lung . Half participant receive anti-TSLP ( MEDI9929 ) top regular asthma treatment , half receive placebo top regular asthma treatment .</brief_summary>
	<brief_title>Effects Anti-TSLP Patients With Asthma</brief_title>
	<detailed_description>The mannitol test increasingly use clinician diagnose asthma . It clinical advantage term feasible wide range setting need minimum equipment . Airway hyper responsiveness ( AHR ) mannitol correlate eosinophilic airway inflammation degree asthma control , predict risk exacerbation response inhale steroid . Subjects asthma indirect AHR increase level intraepithelial carboxypeptidase A3 ( CPA3 ) , metalloexopeptidase specifically express mast cell , compare asthmatic without AHR . CPA3 know selectively present MCTC phenotype ( mast cell contain tryptase chymase ) , recent study suggest increase CPA3 level also constitute marker Th2-high/eosinophilic steroid-responsive asthma . Interestingly , treat mast cell precursor TSLP increase CPA3 immunostaining , suggest TSLP release e.g . airway epithelium up-regulate mast cell phenotype potentially important AHR also promote eosinophilic airway inflammation . Previous publish data investigator confirm increase MCTC submucosa subject asthma associate increase CPA3 TSLP expression . The investigator speculate effect MEDI9929 AHR mannitol likely primarily consequence functional difference mast cell . Treating subject asthma MEDI9929 potentially block downstream effect mast cell activation well eosinophilic inflammation , may reduce AHR inhaled mannitol . The purpose study investigate whether AHR mannitol suitable marker response MEDI9929 , also well understand anti-inflammatory effect MEDI9929 lung , include whether reduce AHR mannitol follow treatment MEDI9929 related reduction chymase/CPA-3 positive mast cell . The investigator hypothesize MEDI9929 decrease response mannitol ( measured increase PD15 ) 12 week treatment compare placebo . It hypothesize number chymase/CPA-3 positive mast cell airway epithelium submucosa reduce 12 week treatment MEDI9929 subject AHR mannitol . This trial offer opportunity study potential biomarkers surrogate endpoint , also identify anti-inflammatory effect MEDI9929 mechanistic level . This study randomize , double-blind , placebo-controlled trial . It include enrolment period maximum 2 week , 12 week treatment ( three IV dose either 700mg MEDI9929 placebo ) 8 week follow-up second bronchoscopy .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Respiratory Hypersensitivity</mesh_term>
	<criteria>1 . Written inform consent 2 . Age 18 75 , inclusive time Visit 1 3 . Body mass index 1840 kg/m2 ( inclusive ) weight ≥ 40 kg Visit 1 . 4 . A diagnosis asthma define GINA ( ginasthma.org ) . 5 . ICS ( dose ) daily basis least three month prior Visit 1 6 . A stable asthma controller regimen ICS ( ±LABA ) least 4 week prior Visit 1 7 . A FEV1 value ≥ 70 % Visit 1 8 . ACQ6 &gt; 1 ( partly control ) Visit 1 9 . PD15 mannitol &lt; = 315 mg visit 1 10 . Subjects must demonstrate acceptable inhaler spirometry technique screen ( evaluate opinion study site staff ) 11 . Subjects must demonstrate ≥ 70 % compliance usual asthma controller ICS±LABA screening ( V1 V3 ) . 1 . Current smoker subject smoke history ≥ 10 pack year . Former smoker &lt; 10 pack year must stop least 6 month eligible . 2 . Previous medical history evidence uncontrolled intercurrent illness . 3 . Any concomitant respiratory disease opinion investigator and/or medical monitor interfere evaluation investigational product interpretation subject safety study result . 4 . Clinically relevant abnormal finding hematology clinical chemistry . 5 . Evidence active liver disease . 6 . History cancer . 7 . Acute upper low respiratory infection . 8 . Helminth parasitic infection . 9 . Known history active tuberculosis ( TB ) . 10 . Positive hepatitis B surface antigen , hepatitis C virus antibody serology . 11 . A positive human immunodeficiency virus ( HIV ) test . 12 . History sensitivity component investigational product . 13 . History anaphylaxis biologic therapy . 14 . History document immune complex disease ( Type III hypersensitivity reaction ) mAb administration . 15 . History known primary immunodeficiency disorder . 16 . Oral corticosteroid . 17 . Use 5lipoxygenase inhibitor . 18 . Use immunosuppressive medication . 19 . Pregnant , breastfeed lactate female . 20 . History chronic alcohol drug abuse . 21 . Receipt Th2 cytokine inhibitor suplatast 22 . Receipt live attenuate vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Airway hyperresponsiveness</keyword>
	<keyword>TSLP</keyword>
	<keyword>Mast cell</keyword>
	<keyword>Eosinophil</keyword>
</DOC>